Form 4: Mirum Pharmaceuticals Officer Trades Stock Options

Mirum Pharmaceuticals President and COO Peter Radovich acquired 16,988 shares of common stock via vested stock options at a price of $19.19 per share.

Summary

• Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc., reported a transaction on June 5, 2026.
• He acquired 16,988 shares of common stock through the exercise of a vested stock option.
• The exercise price for these options was $19.19 per share.
• Following this transaction, Radovich beneficially owns 57,260 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option exercise by an executive, which is a common part of compensation and does not inherently signal new positive or negative company performance.

Positives

• Officer exercised vested stock options, indicating potential confidence in the company's future value.
• The exercise price of $19.19 suggests the current market price may be at or above this level, or the officer anticipates future growth.

Negatives

• The filing details a stock option exercise, which is a planned event for executives and not necessarily indicative of new positive developments.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transaction is a report of a past event.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock option exercises. While these transactions can sometimes signal management's view on the company's prospects, they are often part of pre-planned compensation and exercise strategies.

Stakeholder Impact

• Shareholders: The exercise of stock options by an executive is a routine event and typically has a minimal direct impact on share price unless it signals a broader trend or insider confidence.

Key Dates

Keywords

Form 4, SEC Filing, Mirum Pharmaceuticals, Stock Options, Insider Trading, Executive Compensation, Beneficial Ownership, Peter Radovich